Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
ViewAttendees 2

A1. Novel Agents

Session: Novel Antimicrobial Agents

130 - Design and Preclinical Characterization of SER-155, an Investigational Cultivated Microbiome Therapeutic to Restore Colonization Resistance and Prevent Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

On Demand
Participants should be aware of the following financial/non-financial relationships:
Elizabeth Halvorsen, PhD: Seres Therapeutics (Employee, Shareholder)
Marin Vulic, PhD: Seres Therapeutics (Employee)
Edward J. O'Brien, PhD: Seres Therapeutics (Employee, Shareholder)
Jessica Byrant, PhD: Seres Therapeutics (Employee, Shareholder)
Mary-Jane Lombardo, PhD: Seres Therapeutics (Employee, Shareholder)
Christopher Ford, PhD: Seres Therapeutics (Employee, Shareholder)
Matt Henn, PhD: Seres Therapeutics (Employee, Shareholder)

    Presenting Author(s)

  • Elizabeth Halvorsen, PhD

    Associate Director
    Seres Therapeutics
    Cambridge, MA, United States

    Seres Therapeutics (Employee, Shareholder)

    Slides Slides and Audio

    • Co-Author(s)

  • MV

    Marin Vulic, PhD

    Principal Scientist
    Seres Therapeutics
    Boston, Massachusetts, United States

    Seres Therapeutics (Employee)

  • EO

    Edward J. O'Brien, PhD

    Group Leader, Computational Microbiome Sciences
    Seres Therapeutics
    Cambridge, Massachusetts, United States

    Seres Therapeutics (Employee, Shareholder)

  • JB

    Jessica Byrant, PhD

    Scientist
    Seres Therapeutics
    Cambridge, Massachusetts, United States

    Seres Therapeutics (Employee, Shareholder)

  • ML

    Mary-Jane Lombardo, PhD

    Seres Therapeutics, Inc
    Cambridge, Massachusetts, United States

    Seres Therapeutics (Employee, Shareholder)

  • CF

    Christopher Ford, PhD

    Director
    Seres Therapeutics, Inc
    Cambridge, MA, United States

    Seres Therapeutics (Employee, Shareholder)

  • MH

    Matt Henn, PhD

    Chief Scientific Officer
    Seres Therapeutics, Inc.
    Cambridge, MA, United States

    Seres Therapeutics (Employee, Shareholder)